News

What is Glimepiride

  • Author:Hubei Ocean Biotech Co,.LTd
  • Source:www.oceanchinachem.com
  • Release on :2016-05-31
Glimepiride is a medium- to long-acting sulfonylurea antidiabetic drug. It is marketed as Amaryl by sanofi indiaLtd., GLEAM by Franco Indian Pharmaceuticals,K-GLIM-1 by BLUE CROSS, Glucoryl by Alkem Lab PVT LTD, GLIMPID by Ranbaxy Laboratories(Cardiovascular) and GLIMY by Dr.Reddy's Labs.

It is sometimes classified as either the first third-generation sulfonylurea,or as second-generation.
Like all sulfonylureas, glimepiride acts as an insulin secretagogue.It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.

Not all secondary sufonylureas have the same risks of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.

Hubei Ocean Biotech Co.,Ltd.is a professional chemical industry enterprise, integrating production and trade. Hubei Ocean Biotech Co.,Ltd. has developed into a professional chemicals enterprise which meets different demands from global customers by years' pursuit and striving. We also the Glimepiride supplier in china, if you are interested in our products, please contact us.